Advertisement
AGEN vs PALI
Which Stock Would AI Choose? Agenus (AGEN) vs. Palisade Bio (PALI) Stock Comparison
Key Takeaways
- AGEN is riding a strong momentum wave, up sharply year-to-date on positive clinical and financing catalysts, while PALI has trended lower despite a broad base of bullish analyst coverage.
- AGEN operates in immuno-oncology, whereas PALI focuses on oral therapies for inflammatory bowel disease, making this a cross-specialty biotech comparison.
- Both companies are clinical-stage and pre-profitability, but they carry meaningfully different market capitalizations, cash positions, and near-term catalyst calendars.
- Relative performance has diverged sharply in recent months, with AGEN gaining and PALI declining, reflecting different phases of clinical execution and sentiment.
- Risk profiles differ: AGEN faces near-term dilution and late-stage oncology execution risk, while PALI carries the dilution and data risk typical of an earlier-stage, higher-upside pipeline.
- For additional context on breaking developments and intraday action, explore AGEN Major News and AGEN Today's Price Move, as well as PALI Major News and PALI Today's Price Move.
- To see how automated systems are currently positioned across these and other tickers, browse Trending AI Robots.
Introduction
Investors evaluating small-cap biotechnology often weigh momentum against opportunity, and the comparison between AGEN and PALI captures that tension precisely. Agenus, an immuno-oncology developer, has delivered one of the stronger recent rallies in the sector, while Palisade Bio, an inflammatory bowel disease (IBD) specialist, has declined despite consistent bullish analyst sentiment. This stock comparison is most relevant to traders assessing relative performance and momentum, as well as longer-horizon investors evaluating pipeline-stage risk, cash runway, and catalyst timing. Because the two companies target different disease areas, their market positioning, growth drivers, and risk profiles diverge in instructive ways.
AGEN Overview and Recent Performance
AGEN, or Agenus Inc., is a clinical-stage immuno-oncology company advancing antibody-based therapies, led by the botensilimab plus balstilimab (BOT+BAL) combination. In recent weeks, the stock has been a standout performer, climbing sharply on a strategic pivot toward a registrational Phase 3 program in high-risk microsatellite-stable (MSS) colon cancer. A heavily oversubscribed private placement of up to $340 million, including roughly $85 million in upfront proceeds and warrant tranches that could add substantially more, strengthened the balance sheet and extended the projected cash runway. The company has also secured manufacturing capacity through a collaboration with Zydus Lifesciences and reported growing BOT+BAL product revenue from authorized patient-access programs. This combination of financing, manufacturing clarity, and a defined registrational pathway has driven meaningful positive sentiment and relative outperformance.
PALI Overview and Recent Performance
PALI, or Palisade Bio Inc., is a clinical-stage biopharmaceutical company developing once-daily, oral, locally activated phosphodiesterase-4 (PDE4) inhibitor prodrugs for inflammatory bowel disease. Its lead candidate, PALI-2108, targets ulcerative colitis and fibrostenotic Crohn's disease. During recent market activity, the stock has trended lower despite a notably bullish analyst backdrop: multiple firms have initiated coverage with Buy or Outperform ratings and price targets well above the current share price. The company has reported positive Phase 1 safety and target-engagement data, received regulatory clearance to advance Phase 2 trials, and highlighted a cash position expected to fund operations through key Phase 2 readouts. However, the pre-revenue stage, ongoing net losses, and the timeline before pivotal efficacy data weigh on near-term sentiment.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of automated trading systems from a much larger universe. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers, each built around its own trading style, strategy, timeframe, performance statistics, and set of target symbols. Because no single approach fits every market environment, only the bots best suited to current conditions earn a place in this curated section. This filtering helps traders cut through the noise and identify systems whose recent statistics and positioning align with prevailing trends. Whether you follow biotech momentum or broader market rotations, reviewing Trending AI Robots offers a practical way to see how data-driven models are currently navigating names like these.
Head-to-Head Comparison
The two companies differ most sharply in momentum and catalyst profile. AGEN is in a late-stage execution phase, with financing secured, manufacturing capacity arranged, and a registrational trial design aligned with regulators; its recent rally reflects confidence in a defined, albeit distant, path to potential approval. PALI, by contrast, is earlier in development, transitioning from Phase 1 to Phase 2, with key efficacy readouts not expected until later. Its share price has fallen even as analysts project substantial upside, creating a wide gap between market pricing and consensus targets. Sector exposure also differs: Agenus competes in a crowded, large-cap-dominated oncology landscape, while Palisade Bio operates in IBD, where an oral, locally activated therapy could address unmet demand. On risk, both carry dilution and binary data risk, but Agenus carries higher short interest and beta, while Palisade Bio carries the uncertainty of unproven Phase 2 efficacy and a smaller commercial footprint.
Tickeron AI Verdict
Based on observable factors such as trend consistency, recent price behavior, financing stability, and catalyst clarity, Tickeron's AI would likely favor AGEN in the current environment. The stock's established uptrend, strengthened balance sheet, and defined registrational pathway represent a more favorable near-term positioning than PALI's ongoing downtrend, despite Palisade Bio's strong analyst consensus and long-run upside potential. That said, the assessment is probabilistic rather than definitive: momentum can reverse, and Palisade Bio's forthcoming Phase 2 catalysts could shift the picture. Investors should weigh trend strength against the longer-horizon opportunity each pipeline represents.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AGEN is a Hold and PALI is a Hold.
AGEN's Stochastic Oscillator driving into overbought zone
The Stochastic Oscillator for AGEN moved into overbought territory on November 10, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bearish Trend Analysis
AGEN moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for AGEN crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AGEN's RSI Indicator exited the oversold zone, 30 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on AGEN as a result. In 64 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for AGEN just turned positive on October 29, 2026. Looking at past instances where AGEN's MACD turned positive, the stock continued to rise in 36 of 45 cases over the following month. The odds of a continued upward trend are 80%.
Following a +6.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where AGEN advanced for three days, in 219 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Aroon Indicator entered an Uptrend today. In 64 of 94 cases where AGEN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 68%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. AGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.622) is normal, around the industry mean (3.498). P/E Ratio (2.383) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.994) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Momentum Indicator for PALI turns negative, indicating new downward trend
PALI saw its Momentum Indicator move below the 0 level on October 16, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 95 similar instances where the indicator turned negative. In 90 of the 95 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PALI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for PALI entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where PALI's RSI Indicator exited the oversold zone, 32 of 38 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 67 of 72 cases where PALI's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for PALI just turned positive on November 04, 2026. Looking at past instances where PALI's MACD turned positive, the stock continued to rise in 37 of 41 cases over the following month. The odds of a continued upward trend are 90%.
Following a +11.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where PALI advanced for three days, in 168 of 198 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
PALI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.618) is normal, around the industry mean (3.498). P/E Ratio (1.738) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (526.316) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. PALI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PALI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
AGEN | PALI | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 75 | 54 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 54 Fair valued | 76 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 98 | |
PRICE GROWTH RATING 1..100 | 37 | 83 | |
P/E GROWTH RATING 1..100 | 12 | 97 | |
SEASONALITY SCORE 1..100 | 49 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AGEN's Valuation (54) in the Biotechnology industry is in the same range as PALI (76) in the null industry. This means that AGEN’s stock grew similarly to PALI’s over the last 12 months.
AGEN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as PALI (100) in the null industry. This means that AGEN’s stock grew similarly to PALI’s over the last 12 months.
PALI's SMR Rating (98) in the null industry is in the same range as AGEN (100) in the Biotechnology industry. This means that PALI’s stock grew similarly to AGEN’s over the last 12 months.
AGEN's Price Growth Rating (37) in the Biotechnology industry is somewhat better than the same rating for PALI (83) in the null industry. This means that AGEN’s stock grew somewhat faster than PALI’s over the last 12 months.
AGEN's P/E Growth Rating (12) in the Biotechnology industry is significantly better than the same rating for PALI (97) in the null industry. This means that AGEN’s stock grew significantly faster than PALI’s over the last 12 months.
| AGEN | PALI | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 81% | 2 days ago 84% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 80% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 80% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 83% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Advances ODDS (%) | 8 days ago 84% | 8 days ago 85% |
| Declines ODDS (%) | 10 days ago 90% | 6 days ago 90% |
| BollingerBands ODDS (%) | N/A | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 68% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AGEN’s FA Score shows that 1 FA rating(s) are green while PALI’s FA Score has 0 green FA rating(s).
- AGEN’s FA Score: 1 green, 4 red.
- PALI’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AGEN’s TA Score shows that 5 TA indicator(s) are bullish while PALI’s TA Score has 5 bullish TA indicator(s).
- AGEN’s TA Score: 5 bullish, 4 bearish.
- PALI’s TA Score: 5 bullish, 3 bearish.
Price Growth
AGEN (@Biotechnology) experienced а +5.25% price change this week, while PALI (@Biotechnology) price change was -8.13% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
AGEN is expected to report earnings on Mar 16, 2027.
PALI is expected to report earnings on Mar 31, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
AGEN and
Correlation & Price change
A.I.dvisor indicates that over the last year, AGEN has been closely correlated with TAOX. These tickers have moved in lockstep 91% of the time. This A.I.-generated data suggests there is a high statistical probability that if AGEN jumps, then TAOX could also see price increases.
| Ticker / NAME | Correlation To AGEN | 1D Price Change % | ||
|---|---|---|---|---|
| AGEN | 100% | -1.82% | ||
| TAOX - AGEN | 91% Closely correlated | -5.15% | ||
| PALI - AGEN | 81% Closely correlated | -5.04% | ||
| AXON - AGEN | 42% Loosely correlated | -0.21% | ||
| AMRN - AGEN | 37% Loosely correlated | +0.09% | ||
| QTTB - AGEN | 36% Loosely correlated | -0.11% | ||
More | ||||
PALI and
Correlation & Price change
A.I.dvisor indicates that over the last year, PALI has been closely correlated with RNAC. These tickers have moved in lockstep 81% of the time. This A.I.-generated data suggests there is a high statistical probability that if PALI jumps, then RNAC could also see price increases.
| Ticker / NAME | Correlation To PALI | 1D Price Change % | ||
|---|---|---|---|---|
| PALI | 100% | -5.04% | ||
| RNAC - PALI | 81% Closely correlated | -1.85% | ||
| AGEN - PALI | 81% Closely correlated | -1.82% | ||
| NCNA - PALI | 81% Closely correlated | -2.38% | ||
| TAOX - PALI | 81% Closely correlated | -5.15% | ||
| NRXP - PALI | 74% Closely correlated | -0.84% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| CLOC | 24.95 | 0.01 | +0.02% |
| AAM Crescent CLO ETF (CLOC) | |||
| QDTE | 26.31 | -0.10 | -0.38% |
| Roundhill Nasdaq-100 0DTE Covered Call Strategy ETF (QDTE) | |||
| FCAL | 48.03 | -0.26 | -0.54% |
| First Trust California Municipal High Income ETF (FCAL) | |||
| AVEM | 85.11 | -0.60 | -0.70% |
| Avantis Emerging Markets Equity ETF (AVEM) | |||
| TYLG | 38.56 | -0.43 | -1.11% |
| Global X Information Technology Covered Call & Growth ETF (TYLG) | |||